Raphas Co. Ltd (214260) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Raphas Co. Ltd (214260) has a cash flow conversion efficiency ratio of -0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-452.25 Million ≈ $-306.48K USD) by net assets (₩32.62 Billion ≈ $22.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Raphas Co. Ltd (214260) defensive interval to measure how many days the company can operate on defensive assets alone.
Raphas Co. Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Raphas Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Raphas Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Raphas Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
T Scientific Co.Ltd
KQ:057680
|
-0.008x |
|
Tinka Resources Limited
V:TK
|
-0.006x |
|
IGM Biosciences Inc
NASDAQ:IGMS
|
-0.503x |
|
Sequans Communications SA
NYSE:SQNS
|
-0.204x |
|
Equity Metals Corp
V:EQTY
|
-0.520x |
|
Kafein Yazilim
IS:KFEIN
|
0.024x |
|
SK Innovation Co Ltd Pref
KO:096775
|
0.056x |
Annual Cash Flow Conversion Efficiency for Raphas Co. Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Raphas Co. Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 214260 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩29.36 Billion ≈ $19.90 Million |
₩4.88 Billion ≈ $3.31 Million |
0.166x | +397.25% |
| 2023-12-31 | ₩32.31 Billion ≈ $21.89 Million |
₩-1.81 Billion ≈ $-1.23 Million |
-0.056x | +36.98% |
| 2022-12-31 | ₩40.93 Billion ≈ $27.74 Million |
₩-3.63 Billion ≈ $-2.46 Million |
-0.089x | -639.31% |
| 2021-12-31 | ₩52.36 Billion ≈ $35.48 Million |
₩862.01 Million ≈ $584.17K |
0.016x | -19.52% |
| 2020-12-31 | ₩44.18 Billion ≈ $29.94 Million |
₩903.85 Million ≈ $612.53K |
0.020x | +135.31% |
| 2019-12-31 | ₩47.83 Billion ≈ $32.42 Million |
₩-2.77 Billion ≈ $-1.88 Million |
-0.058x | -79.15% |
| 2018-12-31 | ₩20.13 Billion ≈ $13.64 Million |
₩-651.09 Million ≈ $-441.23K |
-0.032x | +50.53% |
| 2017-12-31 | ₩23.74 Billion ≈ $16.09 Million |
₩-1.55 Billion ≈ $-1.05 Million |
-0.065x | -- |
About Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more